Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm [Yahoo! Finance]
OnKure Therapeutics, Inc. - Class A (OKUR)
Company Research
Source: Yahoo! Finance
completed its merger with Reneo Pharmaceuticals Inc . The combined company started trading on Monday. Concurrent with the closing of the merger, the company completed a $65 million private placement with a group of new and existing investors. Following the transactions, OnKure is expected to have a cash runway through multiple clinical readouts and into Q4-2026 The analyst initiated coverage with an Outperform rating with a price target of $35 and notes that OKI-219 can become the go-to option for one of the most frequent mutations in breast cancer. “We believe Onkure can address key limitations of currently approved targeted agents by reducing off-target toxicity with greater selectivity,” the analyst writes. The analyst's investment thesis on OnKure revolves around PI3Ka inhibition demonstrated by alpelisib, though its efficacy is limited by toxicity concerns OKI-219 promise as a third-generation PI3Ka inhibitor. Alpelisib is generic name for Novartis AG's (NYSE: NVS ) P
Show less
Read more
Impact Snapshot
Event Time:
OKUR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OKUR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OKUR alerts
High impacting OnKure Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
OKUR
News
- OnKure Therapeutics (NASDAQ: OKUR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- OnKure to Present at the Stifel 2024 Healthcare ConferenceGlobeNewswire
- OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]Yahoo! Finance
- OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer SymposiumGlobeNewswire
- OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond [Seeking Alpha]Seeking Alpha
OKUR
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/7/24 - Form 424B3
- OKUR's page on the SEC website